As of 2025-12-18, the Intrinsic Value of Emergent BioSolutions Inc (EBS) is 10.37 USD. This EBS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 12.21 USD, the upside of Emergent BioSolutions Inc is -15.10%.
The range of the Intrinsic Value is 3.27 - 58.24 USD
Based on its market price of 12.21 USD and our intrinsic valuation, Emergent BioSolutions Inc (EBS) is overvalued by 15.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 3.27 - 58.24 | 10.37 | -15.1% |
| DCF (Growth 10y) | 14.23 - 126.30 | 28.75 | 135.5% |
| DCF (EBITDA 5y) | 11.97 - 17.12 | 13.02 | 6.7% |
| DCF (EBITDA 10y) | 17.88 - 26.51 | 20.24 | 65.8% |
| Fair Value | 14.71 - 14.71 | 14.71 | 20.47% |
| P/E | 18.06 - 22.86 | 19.08 | 56.2% |
| EV/EBITDA | 15.92 - 51.07 | 31.15 | 155.1% |
| EPV | (33.82) - (42.68) | (38.25) | -413.3% |
| DDM - Stable | 12.47 - 53.37 | 32.92 | 169.6% |
| DDM - Multi | (1.58) - (5.23) | (2.42) | -119.8% |
| Market Cap (mil) | 641.27 |
| Beta | 2.25 |
| Outstanding shares (mil) | 52.52 |
| Enterprise Value (mil) | 1,058.87 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.28% |
| Cost of Debt | 5.50% |
| WACC | 6.66% |